Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
Media Centre
Overview
Latest News
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2022
2021
2020
2019
2018
17-May-2022
Kazia marks DIPG Awareness Day
29-Apr-2022
Kazia to present at ASCO
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
28-Apr-2022
Proposed issue of securities - KZA
26-Apr-2022
Kazia establishes ATM program
22-Apr-2022
Proposed issue of securities - KZA
21-Apr-2022
Kazia's paxalisib Phase II trial achieves completion
8-Apr-2022
Kazia presents preclinical data for paxalisib at AACR
8-Apr-2022
Kazia presents on EVT801 at AACR
6-Apr-2022
Kazia response to SEC comments letter
1
2
Next
